Premium
Multidrug resistance mechanisms in chronic lymphocytic leukaemia
Author(s) -
Consoli Ugo,
Santonocito AnnaMaria,
Stagno Fabio,
Fiumara Paolo,
Privitera Antonella,
Parisi Giuseppina,
Giustolisi Giada M.,
Pavone Biagia,
Palumbo Giuseppe A.,
Di Raimondo Francesco,
Milone Guglielmo Giuseppe, Patrizia,
Giustolisi Rosario
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.0007-1048.2002.03344.x
Subject(s) - chronic lymphocytic leukemia , stage (stratigraphy) , p glycoprotein , multiple drug resistance , cd19 , immunology , medicine , cancer research , oncology , leukemia , biology , drug resistance , antibody , genetics , paleontology
Summary. We evaluated the presence of P‐glycoprotein (P‐gp)‐170, multidrug resistance protein (MRP), lung resistance protein (LRP)‐56 and Bcl‐2 in CD19‐positive cells from 100 cases of chronic lymphocytic leukaemia (CLL). P‐gp‐170 was found in 73% of the CLL cases with no significant difference regarding stage or previous treatment. LRP‐56 protein was homogeneously distributed with no differences for stage or treatment. MRP protein was detected at a low level of expression in 49·4% of CLL patients with no differences for stage or treatment. Bcl‐2 protein was expressed at a high level in all CLL patients and higher levels were found in the advanced stage. This leads us to conclude that P‐gp, MRP, LRP‐56 and Bcl‐2 are frequently expressed in CLL. P‐gp, MRP and LRP are not correlated to stage or previous treatment. Bcl‐2 is higher in advanced‐stage patients. The clinical and biological significance of these zMDR mechanisms in CLL remains to be fully explained.